

We Claim:

1. A metered dose inhaler containing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising: an effective amount of mometasone furoate, a dry powder surfactant and HFA 227,
5 wherein the formulation is substantially free of a carrier.
2. The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 1, wherein the mometasone furoate is present in an amount of about 50 µg to about 400 µg.
10
3. The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 2, wherein the mometasone furoate is present in an amount of about 100 µg.
- 15 4. The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 2, wherein the mometasone furoate is present in an amount of about 200 µg.
5. The metered dose inhaler containing an aerosol suspension formulation for
20 inhalation according to claim 2, wherein the mometasone furoate is present in an amount of about 400 µg.
6. The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 1, wherein the dry powder surfactant is selected from

the group consisting of lecithin, stearic acid, palmitic acid, magnesium stearate, magnesium palmitate, and magnesium laureate.

7. The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 1, wherein the formulation is free of additional excipients, and wherein the metered dose inhaler emits a dose having uniform drug content upon actuation of the metered dose inhaler.

8. The metered dose inhaler containing an aerosol suspension formulation for inhalation according to claim 1, wherein the percent of the fine particles dispensed upon actuation of the metered dose inhaler is about 55% to about 85%, and wherein said fine particles have a particle size of less than about 4.7 μ m.

9. The metered dose inhaler according to claim 8, wherein the percent of the fine particles dispensed upon actuation of the metered dose inhaler is about 65% to about 80%, and wherein said fine particles have a particle size of less than about 4.7 μ m.

10. A process for producing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising:

an effective amount of mometasone furoate and a non-chlorofluorocarbon based propellant; wherein the formulation is free of a carrier, comprising the steps of:

a) mixing a dry powder blend of micronized mometasone with a dry powder surfactant to form a uniform mixture;

- b) filling said mixture into a metered dose inhaler canister;
- c) crimping said canister with a metering valve; and
- d) filling said canister with a non-chlorofluorocarbon based propellant.

5 11. The process according to claim 10, wherein the dry powder surfactant is selected from the group consisting of lecithin, stearic acid, palmitic acid, magnesium stearate, magnesium palmitate and magnesium laurate.

10 12. The process according to claim 10, wherein the non-chlorofluorocarbon based propellant is HFA 227.

13. The product produced by the process of claim 10.

15 14. The product of claim 13, wherein the mometasone furoate is present in an amount of about 50 µg to about 400 µg.

15. The product of claim 14, wherein the mometasone furoate is present in an amount of about 100 µg.

20 16. The product of claim 14, wherein the mometasone furoate is present in an amount of about 200 µg.

17. The product of claim 14, wherein the mometasone furoate is present in an amount of about 400 µg.

18. The product of claim 13, wherein the formulation is free of additional excipients, and wherein the metered dose inhaler emits a dose having uniform drug content upon actuation of the metered dose inhaler.

5

19. The product of claim 13, wherein the percent of the fine particles dispensed upon actuation of the metered dose inhaler is about 55% to about 85%, and wherein said fine particles have a particle size of less than about 4.7 μ m.

10

20. The product of claim 19, wherein the percent of the fine particles dispensed upon actuation of the metered dose inhaler is about 65% to about 80%, and wherein said fine particles have a particle size of less than about 4.7 μ m.

15